Urologic complications of HIV and AIDS

Nature Clinical Practice Urology

Volumn 6, Issue 1, 2009, Pages 32-43

  Heyns, Chris F ^a,b   Groeneveld, Adam E ^c   Sigarroa, Nelson B ^d  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c College of Urologists of South Africa ^*  (South Africa)

^d WALTER SISULU UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALITRETINOIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; BLEOMYCIN; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENFUVIRTIDE; INDINAVIR; INTERFERON; METHIONINE; NARCOTIC ANALGESIC AGENT; PACLITAXEL; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TENOFOVIR; TESTOSTERONE; TUBERCULOSTATIC AGENT; VINCA ALKALOID; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; BLADDER DYSFUNCTION; CIRCUMCISION; CLINICAL TRIAL; CRYSTALLURIA; ERECTILE DYSFUNCTION; FOURNIER GANGRENE; GLOMERULOPATHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED NEPHROPATHY; INTERSTITIAL NEPHRITIS; KAPOSI SARCOMA; KIDNEY ABSCESS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY TUBERCULOSIS; KIDNEY TUBULE DISORDER; MALE INFERTILITY; NEPHRECTOMY; NEPHROLITHIASIS; NEPHROTOXICITY; ORCHITIS; PENIS CANCER; PREVALENCE; PRIORITY JOURNAL; PROSTATE ABSCESS; PROSTATE CANCER; PROSTATE DISEASE; PROSTATITIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SCHISTOSOMIASIS; TESTIS TUMOR; URINARY TRACT DISEASE; URINARY TRACT INFECTION; UROLITHIASIS; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; HIV INFECTIONS; HUMANS; MALE; UROLOGIC DISEASES;

EID: 58649104471     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1273     Document Type: Review

References (134)

1. WHO (online 20 November 2007) Global HIV prevalence has levelled off. [http://www.who.int/mediacentre/news/releases/2007/pr61/en/]
2. Buvé A et al. (2002) The spread and effect of HIV-1 infection in sub-Saharan Africa. Lancet 359: 2011-2017
3. HIV and AIDS in Africa [http://www.avert.org/aafrica.htm]
4. UNAIDS (online 20 November 2007) 2007 AIDS epidemic update. [http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/ EpiUpdArchive/2007/]
5. UNAIDS/WHO (2006) AIDS epidemic update: December 2006. [http://data.unaids.org/pub/EpiReport/2006/]
6. Lebovitch S and Mydlo JH (2008) HIV-AIDS-urologic considerations. Urol Clin N Am 35: 59-68
7. Roe J et al. (2008) HIV care and the incidence of acute renal failure. Clin Infect Dis 47: 242-249
8. Rieke A (2007) HIV and renal function. In HIV Medicine 2007, 567-580 (Eds Hoffmann C et al.) [http://www.hivmedicine.com/ hivmedicine2007.pdf] (accessed 1 December 2008)
9. Shah SN et al. (2006) Update on HIV-associated nephropathy. Curr Opin Nephrol Hypertens 15: 450-455
10. Gerntholtz TE et al. (2006) HIV-related nephropathy: A South African perspective. Kidney Int 69: 1885-1891
11. Atta MG et al. (2008) HIV-associated nephropathy: Epidemiology, pathogenesis, diagnosis and management. Expert Rev Anti Infect Ther 6: 365-371
12. Janakiraman H et al. (2008) Correlation of CD4 counts with renal disease in HIV positive patients. Saudi J Kidney Dis Transpl 19 603-607
13. Comiter S et al. (1992) Ureteral obstruction in a patient with Burkitt's lymphoma and AIDS. Urology 39: 277-280
14. Hyun G and Lowe CF (2003) AIDS and the urologist. Urol Clin N Am 30: 101-109
15. Heyns CF and Fisher M (2005) The urological management of the patient with acquired immunodeficiency syndrome. BJU Int 95: 709-716
16. Gruber SA et al. (2008) Preliminary experience with renal transplantation in HIV+ recipients: Low acute rejection and infection rates. Transplantation 86: 269-274
17. Miles BJ et al. (1989) The urological manifestations of the acquired immunodeficiency syndrome. J Urol 142: 771-773
18. Zouiten F et al. (2003) Bacterial infections in AIDS (mycobacterial infections excluded): Study of 100 cases [French]. Tunis Med 81: 113-120
19. Hoepelman AI et al. (1992) Bacteriuria in men infected with HIV-1 is related to their immune status (CD4+ cell count). AIDS 6: 179-184
20. Lee LK et al. (2001) The urologist and the patient infected with human immunodeficiency virus or with acquired immunodeficiency syndrome. BJU Int 88: 500-510
21. Schönwald S et al. (1999) Urinary tract infections in HIV disease. Int J Antimicrob Agents 11: 309-311
22. Kwan DJ and Lowe FC (1995) Genitourinary manifestations of the acquired immunodeficiency syndrome. Urology 45: 13-27
23. Vignesh R et al. (2008) Urinary infections due to multi-drug-resistant Escherichia coli among persons with HIV disease at a tertiary AIDS care centre in South India. Nephron Clin Pract 110: C55-c57
24. Steele BW and Carson CC (1997) Recognizing the urologic manifestations of HIV and AIDS. Contemp Urol 9: 39-53
25. Kaplan MS et al. (1987) Urologic manifestations of AIDS. Urology 30: 441-443
26. O'Regan S et al. (1990) AIDS and the urinary tract. J Acquir Immune Defic Syndr 3: 244-251
27. Rey D et al. (1999) Isolated renal Aspergillus abscess in an AIDS patient with a normal CD4+ cell count on highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 18: 137-141
28. Padoveze MC et al. (2002) Nosocomial infections among HIV-positive and HIV-negative patients in a Brazilian infectious diseases unit. Am J Infect Control 30: 346-350
29. Menéndez V et al. (1995) Neurogenic bladder in patients with acquired immunodeficiency syndrome. Neurourol Urodyn 14: 253-257
30. Hermieu JF et al. (1996) Micturition disturbances and human immunodeficiency virus infection. J Urol 156: 157-159
31. Gyrtrup HJ et al. (1995) Voiding problems in patients with HIV infection and AIDS. Scand J Urol Nephrol 29: 295-298
32. Gluckman GR and Werboff LH (1994) Toxoplasmosis of the bladder: Case report and review of the literature. J Urol 151: 1629-1630
33. Figueiredo AA et al. (2008) Urogenital tuberculosis in immunocompromised patients. Int Urol Nephrol [doi:10.1007/ s11255-008-9436-6]
34. Centers for Disease Control and Prevention (online 28 January 2008) TB and HIV/AIDS. [http://www.cdc.gov/hiv/resources/factsheets/hivtb.htm]
35. Dean GL et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16:75-83
36. Cek M et al. for the Members of the Urinary Tract Infection (UTI) Working Group of the European Association of Urology (EAU) Guidelines Office (2005) EAU guidelines for the management of genitourinary tuberculosis. Eur Urol 48: 353-362
37. Manosuthi W et al. (2006) Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect Dis 53: 357-363
38. Colebunders R et al. (2006) Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 10: 946-953
39. Leport C et al. (1989) Bacterial prostatitis in patients infected with the human immunodeficiency virus. J Urol 141: 334-336
40. Trauzzi SJ et al. (1994) Management of prostatic abscess in patients with human immunodeficiency syndrome. Urology 43: 629-633
41. Gebo KA (2002) Prostatic tuberculosis in an HIV infected male. Sex Transm Infect 78: 147-148
42. Hedayati T and Kwon DS (online 5 November 2007) Prostatitis. [http://www.emedicine.com/emerg/topic488.htm]
43. Wise GJ and Shteynshlyuger A (2006) How to diagnose and treat fungal infections in chronic prostatitis. Curr Urol Rep 7: 320-328
44. Kahn DG and Thommes J (1992) Granulomatous orchitis and epididymitis secondary to Histoplasma capsulatum and CMV in AIDS [abstract #PuB 7267]. In Proceedings of the International Conference on AIDS: 1992 July 19-24; Amsterdam, The Netherlands
45. Ayan F et al. (2005) Fournier's gangrene: A retrospective clinical study on forty-one patients. ANZ J Surg 75: 1055-1058
46. Corman JM et al. (1999) Fournier's gangrene in a modern surgical setting: Improved survival with aggressive management. BJU Int 84: 85-88
47. Dahm P et al. (2000) Outcome analysis in patients with primary necrotizing fasciitis of the male genitalia. Urology 56: 31-35
48. Jeong HJ et al. (2005) Prognostic factors in Fournier gangrene. Int J Urol 12: 1041-1044
49. Mindrup SR et al. (2005) Hyperbaric oxygen for the treatment of Fournier's gangrene. J Urol 173: 1975-1977
50. Secor WE and Sundstrom JB (2007) Below the belt: New insights into potential complications of HIV-1/schistosome coinfections. Curr Opin Infect Dis 20: 519-523
51. Harms G and Feldmeier H (2005) The impact of HIV infection on tropical diseases. Infect Dis Clin North Am 19: 121-135
52. Kjetland EF et al. (2006) Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS 20: 593-600
53. Gallagher M et al. (2005) The effects of maternal helminth and malaria infections on mother-to-child HIV transmission. AIDS 19 1849-1855
54. Mwanakasale V et al. (2003) Interactions between Schistosoma haematobium and human immunodeficiency virus type 1: The effects of coinfection on treatment outcomes in rural Zambia. Am J Trop Med Hyg 69: 420-428
55. Nutankalva L et al. (2008) Malignancies in HIV: Pre- and post-highly active antiretroviral therapy. J Natl Med Assoc 100 817-820
56. Mayor AM et al. (2008) AIDS-defining neoplasm prevalence in a cohort ot HIV-infected patients, before and after highly active antiretroviral therapy. Ethn Dis 18(Suppl 2): S189-S194
57. Lewden C et al. for the ANRS EN19 Mortalité Study Group and Mortavic1 (2008) Changes in causes at death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 48: 590-598
58. Engels EA et al. for the HIV/AIDS Cancer Match Study (2006) Trends in cancer risk among people with AIDS in the United States: 1980-2002. AIDS 20: 1645-1654
59. Patel P et al. for the Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148 728-736
60. Spano JP et al. (2008) AIDS-related malignancies: State of the art and therapeutic challenges. J Clin Oncol [doi:10.1200/ JCO.2008.16.8252]
61. Demopoulos BP et al. (2003) Non-acquired immunodeficiency syndrome-defining malignancies in patients infected with human immunodeficiency virus. Arch Pathol Lab Med 127: 589-592
62. Bedimo R (2008) Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/ AIDS Rep 5: 140-149
63. Bellan C et al. (2003) Pathologic aspects of AIDS malignancies. Oncogene 22: 6639-6645
64. Rosso R et al. (2008) Infectious complications of cancer chemotherapy in HIV patients. Curr Infect Dis Rep 10: 149-156
65. Lowe FC et al. (1989) Kaposi's sarcoma of the penis in patients with acquired immunodeficiency syndrome. J Urol 142: 1475-1477
66. Schöfer H and Sachs DL (2007) Kaposi's sarcoma. In HIV Medicine 2007, 477-488 (Eds Hoffmann C et al.) [http://www.hivmedicine.com/hivmedicine2007.pdf] (accessed 1 December 2008)
67. Tappero JW et al. (1993) Kaposi's sarcoma: Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Darmatol 28: 371-395
68. Klein LT and Lowe FC (1995) Penile gangrene associated with extensive Kaposi's sarcoma in patients with the acquired immunodeficiency syndrome. Urology 46: 425-428
69. Lichterfeld M et al. (2005) Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection 33: 140-147
70. Martin-Carbonero L et al. (2004) Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 18: 1737-1740
71. Tulpule A et al. (2002) Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 95: 147-154
72. Swierzewski SJ III et al. (1993) The management of meatal obstruction due to Kaposi's sarcoma of the glans penis. J Urol 150: 193-195
73. Nguyen HQ et al. (2008) Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: Characterizing the predictors of clinical response. AIDS 22: 937-945
74. Goedert JJ et al. (2007) Risk of germ cell tumors among men with HIV/acquired immunodeficiency syndrome. Cancer Epidemiol Biomarkers Prev 16: 1266-1269
75. Frisch M et al. for the AIDS-Cancer Match Registry Study Group (2001) Association of cancer with AIDS-related immunosuppression in adults. JAMA 285: 1736-1745
76. Hausen HZ and Villiers ED (1994) Human papilloma viruses. Annu Rev Microbiol 48: 427-447
77. Leibovitch I and Goldwasser B (1994) The spectrum of acquired immunodeficiency syndrome-associated testicular disorders. Urology 44: 818-824
78. Hoffmann C (2007) Malignant lymphomas. In HIV Medicine 2007, 489-509 (Eds Hoffmann C et al.) [http://www.hivmedicine.com/ hivmedicine2007.pdf] (accessed 1 December 2008)
79. Burmer GC et al. (1993) Squamous cell carcinoma of the scrotum associated with human papillomaviruses. J Urol 149: 374-377
80. Parker DC et al. (online 7 September 2006) Dermatologic diseases of the male genitalia: Malignant. [http://www.emedicine.com/med/ TOPIC3345.HTM]
81. Culkin DJ and Beer TM (2003) Advanced penile carcinoma. J Urol 170: 359-365
82. Sirera G et al. (2006) High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. AIDS 120: 1201-1204
83. Hadjivassiliou M et al. (2007) Human papillomavirus assay in genital warts - correlation with symptoms. Int J STD AIDS 18 329-334
84. Kreuter A et al. for the German Competence Network HIV/AIDS (2008) Penile intraepithelial neoplasia is frequent in HIV-positive men with anal dysplasia. J Invest Dermatol 128: 2316-2324
85. Sumino Y et al. (2004) Urethral condyloma acuminata following urethral instrumentation in an elderly man. Int J Urol 11: 926-930
86. Nguyen P et al. (2002) Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 138: 827-828
87. Manfredi R et al. (2006) Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features: Open questions for urologists, oncologists, and infectious disease specialists. Cancer Detect Prev 30: 20-23
88. Silberstein J et al. (2008) HIV and prostate cancer: A systematic review of the literature. Prostate Cancer Prostatic Dis [doi:10.1038/pcan.2008.44]
89. Vianna LE et al. (2006) Serum prostate-specific antigen levels in older men with or at risk of HIV infection. HIV Med 7: 471-476
90. Quatan N et al. (2005) Should HIV patients be considered a high risk group for the development of prostate cancer? Ann R Coll Surg Engl 87: 437-438
91. Levinson A et al. (2005) Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology 65: 91-94
92. Lallemand F et al. (2002) Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr 30: 187-190
93. Schrooten W et al. for the Eurosupport Study Group (2001) Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 15: 1019-1023
94. Sollima S et al. (2001) Protease inhibitors and erectile dysfunction. AIDS 15: 2331-2333
95. Lamba H et al. (2004) Antiretroviral therapy is associated with sexual dysfunction and with increased serum estradiol levels in men. Int J STD AIDS 15: 234-237
96. Crum NF et al. (2005) A review of hypogonadism and erectile dysfunction and HIV infected men during the pre-and post HMRT eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS 19: 655-671
97. Alciati A et al. (2007) Major depression-related immunological changes and combination antiretrovirai therapy in HIVB-seropositive patients. Hum Psychopharmacol 22: 33-40
98. Fava M et al. (2006) Efficacy and safety of sildenafil in men with serotonergic antidepressant associated erectile dysfunction: Results from a randomized, double blind placebo controlled trial. J Clin Psychiatry 67: 240-246
99. Ende AR et al. (2006) Erectile dysfunction in an urban HIV-positive population. AIDS Patient Care STDS 20: 75-78
100. Srinivas-Shankar U and Wu FCW (2006) Drug insight: Testosterone preparations. Nat Clin Pract Urol 3: 653-665
101. Karlovsky M et al. (2004) Increasing incidence and importance of HIV/AIDS and gonorrhea among men aged >50 in tbe US in the era of erectile dysfunction therapy. Scan J Urol Nephrol 38: 247-252
102. Benotsch EG et al. (2006) Substance use, medications for sexual facilitation, and sexual risk behavior among traveling men who have sex with men. Sex Transm Dis 33: 706-711
103. Nurnberg HG and Duttagupta S (2004) Economic analysis of sildenafil citrate (Viagra) add-on to treat erectile dysfunction associated with selective serotonin reuptake inhibitor use. Am J Ther 11: 9-12
104. Sadeghi-Nejad H et al. (2000) Erectile dysfunction in the HIV-positive male: A review of medical, legal and ethical considerations in the age of oral pharmacotherapy. Int J Impot Res 12(Suppl 3) S49-S53
105. Sonnenberg-Schwan U et al. (2007) HIV and wish for parenthood. In HIV Medicine 2007, 685-694 (Eds Hoffmann C et al.) [http://www.hivmedicine.com/hivmedicine2007.pdf] (accessed 1 December 2008)
106. Semprini AE et al. (1992) Insemination of HIV-negative women with processed semen of HIV-positive partners. Lancet 340: 1317-1319
107. Garrido N et al. (2004) Report of the results of a 2 year programme of sperm wash and ICSI treatment for human immunodeficiency virus and hepatitis C virus serodiscordant couples. Hum Reprod 19: 2581-2586
108. Heylen R and Miller R (1997) Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV-positive patients: Part 2. Genitourin Med 73: 5-11
109. Tashima KT et al. (1997) Indinavir nephropathy. N Engl J Med 336: 138-139
110. Bruce RG et al. (1997) Urolithiasis associated with the protease inhibitor indinavir. Urology 50: 513-518
111. Daudon M et al. (1997) Urinary stones in HIV-1 positive patients treated with indinavir. Lancet 349: 1294-1295
112. Kalaitzis C et al. (2007) Urological management of indinavir-associated acute renal failure in HIV-positive patients. Int Urol Nephrol 39: 743-746
113. Dieleman JP et al. (1999) Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 13: 473-478
114. Collin F et al. (2007) Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults. Ther Drug Monit 29: 164-170
115. Kohan AD et al. (1999) Indinavir urolithiasis: An emerging cause of renal colic in patients with human immunodeficiency virus. J Urol 161: 1765-1768
116. Meraviglia P et al. (2002) Risk factors for indinavir-related renal colic in HIV patients: Predictive value of indinavir dose/body mass index. AIDS 16: 2089-2093
117. Nadler RB et al. (2003) The etiology of urolithiasis in HIV-infected patients. J Urol 169: 475-477
118. Salahuddin S et al. (2001) Is indinavir crystalluria an indicator for indinavir stone formation? AIDS 15: 1079-1080
119. Wu DS and Stoller ML (2000) Indinavir urolithiasis. Curr Opin Urol 10: 557-561
120. Gentle DL et al. (1997) Protease inhibitor-induced urolithiasis. Urology 50: 508-511
121. Harris M (2008) Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Expert Opin Drug Saf 7: 389-400
122. Rho M and Perazella MA (2007) Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Curr Drug Saf 2: 147-154
123. Weiss HA et al. (2000) Male circumcision and risk of HIV infection in sub-Saharan Africa: A systematic review and meta-analysis. AIDS 14: 2361-2370
124. Patterson BK et al. (2002) Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 161: 867-873
125. Soilleux EJ and Coleman N (2004) Expression of DC-SIGN in human foreskin may facilitate sexual transmission of HIV. J Clin Pathol 57: 77-78
126. McCoombe SG and Short RV (2006) Potential HIV-1 target cells in the human penis. AIDS 20: 1491-1495
127. Fink AJ (1986) A possible explanation for heterosexual male infection with AIDS. N Engl J Med 315: 1167
128. Moses S et al. (1999) Analysis of the scientific literature on male circumcision and risk for HIV infection. Int J STD AIDS 10 626-628
129. Drain PK et al. (2006) Male circumcision, religion, and infectious diseases: An ecologic analysis of 118 developing countries. BMC Infect Dis 6: 172
130. Weiss HA et al. (2008) Male circumcision for HIV prevention: From evidence to action? AIDS 22: 567-574
131. Auvert B et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 Trial. PLoS Med 2: E298
132. Bailey RC et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 369: 643-656
133. Gray RH et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: A randomised trial. Lancet 369: 657-666
134. Krieger JN and Heyns CF: Male circumcision and HIV/AIDS risk - analysis of the scientific evidence. Afr J Urol, in press